Loading organizations...
§ Private Profile · Cambridge, MA, USA
"If-then" conditional logic for protein drugs
SynsoryBio has raised $500K across 1 funding round.
Key people at SynsoryBio.
SynsoryBio was founded in 2023 by Nathan Tague (Founder) and Elliot Tague (Founder).
SynsoryBio has raised $500K in total across 1 funding round.
SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.
Key people at SynsoryBio.
SynsoryBio was founded in 2023 by Nathan Tague (Founder) and Elliot Tague (Founder).
SynsoryBio has raised $500K in total across 1 funding round.
SynsoryBio's investors include Y Combinator.
SynsoryBio is a biotechnology startup founded in 2023 in Cambridge, MA, focused on developing next-generation protein therapeutics that incorporate "if-then" conditional logic. Their protein drugs sense specific disease markers in the body and activate only at diseased tissues, enhancing efficacy while minimizing side effects. This approach addresses critical challenges in treating diseases such as cancer and autoimmune disorders by expanding the therapeutic window of potent drugs. For an investment firm, SynsoryBio represents a cutting-edge opportunity in synthetic biology and protein engineering, targeting high-impact sectors like oncology and immunotherapy with transformative potential for patient outcomes and healthcare innovation[1][3].
As a portfolio company, SynsoryBio builds protein therapeutics that serve patients with difficult-to-treat diseases, including solid tumors and blood cancers. Their products solve the problem of systemic toxicity and dose limitations common in powerful immunotherapies by localizing drug activity to diseased tissues only. The company has demonstrated promising preclinical results, including tumor shrinkage in resistant cancers, and is advancing multiple Phase I clinical trials, signaling strong growth momentum and validation of their technology platform[2][3].
SynsoryBio was founded in 2023 by brothers Elliot and Nathan, both PhD holders in biomedical engineering with backgrounds in synthetic biology from Boston University and Harvard Medical School. Their expertise in engineering protein therapeutics with synthetic sensing capabilities led to the creation of the company. The idea emerged from the need to overcome safety and efficacy limitations of current cancer immunotherapies by enabling drugs to "know" their location in the body and activate conditionally. Early traction includes multiple patent filings, preclinical successes, and ongoing clinical trials targeting cancer and neuroscience applications, marking pivotal moments in their development[1][3].
SynsoryBio rides the wave of precision medicine and synthetic biology, leveraging advances in protein engineering to create smarter, safer therapeutics. The timing is critical as the demand for more effective cancer immunotherapies with fewer side effects grows, and the ability to target previously undruggable proteins (e.g., BCL6 in blood cancers) opens new therapeutic avenues. Market forces such as increasing investment in biotech innovation, regulatory support for targeted therapies, and unmet clinical needs favor SynsoryBio’s approach. Their technology could influence the broader ecosystem by setting new standards for conditional drug activation and expanding the scope of protein therapeutics in complex diseases[1][2][3].
Looking ahead, SynsoryBio is poised to advance its clinical pipeline with expected trial readouts starting in early 2025, particularly in breast cancer and blood cancers. Trends shaping their journey include growing adoption of synthetic biology in drug development, increasing focus on tissue-selective therapies, and breakthroughs in crossing biological barriers like the blood-brain barrier for CNS diseases. As their platform matures, SynsoryBio’s influence may expand beyond oncology into neuroscience and autoimmune disorders, potentially transforming therapeutic paradigms by making highly potent drugs safer and more effective. Their continued innovation in conditional logic protein drugs ties back to their mission of revolutionizing treatment specificity and patient outcomes[2][3].
SynsoryBio has raised $500K across 1 funding round. Most recently, it raised $500K Seed in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $500K Seed | — | Y Combinator | Announced |
